Brain metastases in NSCLC increase clinical complexity, but prognosis is not determined solely by the phrase “it spread to the brain.” Key drivers include the number of lesions (single/oligometastatic vs multiple), size and symptoms, molecular profile, and response to systemic therapy. Modern management may combine stereotactic radiosurgery (SRS), surgery in selected cases, whole-brain radiotherapy (WBRT) when appropriate, and systemic treatment. For patients with actionable mutations, certain targeted therapies demonstrate meaningful central nervous system activity and can help control brain disease. The best plan comes from coordinated imaging review, neuro-oncology input, and an individualized multimodal strategy focused on control and quality of life.